✦ LIBER ✦

PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL

✍ Scribed by E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN34 BUDGET IMPACT ANALYSIS OF DASATINI

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN11 COST-UTILITY ANALYSIS OF DASATINIB

✍ JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN14 THE COST AND COST EFFECTIVENESS OF

✍ Juarez-Garcia, A; Uc-Coyoc, R; Hernandez-Rivera, G; Rangel, S; Taylor, MJ; Lital 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

PCN69 COST-EFFECTIVENESS ANALYSIS OF DAS

✍ de Ramirez; A Arellano; U Sbarigia; MJ Taylor; P Martin; G Restovic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Efficacy and safety of dasatinib versus

✍ Fujisawa, Shin; Nakamae, Hirohisa; Ogura, Michinori; Ishizawa, Ken-ichi; Taniwak 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 367 KB